Compare CXDO & NBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CXDO | NBP |
|---|---|---|
| Founded | 1995 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 189.9M | 205.9M |
| IPO Year | 1999 | 2019 |
| Metric | CXDO | NBP |
|---|---|---|
| Price | $5.83 | $1.38 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | ★ $9.20 | $9.00 |
| AVG Volume (30 Days) | 269.7K | ★ 594.7K |
| Earning Date | 05-05-2026 | 04-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 166.67 | N/A |
| EPS | ★ 0.05 | N/A |
| Revenue | ★ $68,167,000.00 | N/A |
| Revenue This Year | $45.26 | N/A |
| Revenue Next Year | $13.31 | N/A |
| P/E Ratio | $117.20 | ★ N/A |
| Revenue Growth | ★ 12.05 | N/A |
| 52 Week Low | $5.54 | $1.32 |
| 52 Week High | $11.23 | $5.19 |
| Indicator | CXDO | NBP |
|---|---|---|
| Relative Strength Index (RSI) | 42.92 | 27.50 |
| Support Level | $5.55 | N/A |
| Resistance Level | $6.76 | $1.67 |
| Average True Range (ATR) | 0.18 | 0.06 |
| MACD | 0.06 | -0.03 |
| Stochastic Oscillator | 48.15 | 15.19 |
Crexendo Inc is a software technology company that provides cloud communication platform software and unified communications as a service (UCaaS) offering, including voice, video, contact center, and managed IT services. The company operates through two segments: Cloud Telecommunications Services and Software Solutions. Its cloud telecommunications segment generates revenue from the provision of broadband Internet services, managed IT services, software license sales, and infrastructure as a service. The software solutions segment derives revenues from three primary sources: software licenses, software maintenance support and professional services. The majority of the company's revenue is derived from the Cloud Telecommunications Services segment.
NovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. Its inventive immuno-oncology pipeline consists of three clinical stage programs, givastomig; uliledlimab; and ragistomig. Its core product, givastomig, is a potential in-class CLDN18.2 bispecific antibody for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies.